I prefer more accurate math Bio-t-gel has much greater revenue projections then you estimate. Common $1 million that workout $10 - $15 for Teva. I have linked a more realistic projection.
And this only for the US. Biosante still owns the rights to the rest of the world. Teva is in over 60 countries. I see another agreement with Teva for the rest of the world down the road once Bio-t-gel marketing in the US is established.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.